The Role of Pharmacometrics in Advancing the Therapies for Autoimmune Diseases

Bibliographic Details
Title: The Role of Pharmacometrics in Advancing the Therapies for Autoimmune Diseases
Authors: Artur Świerczek, Dominika Batko, Elżbieta Wyska
Source: Pharmaceutics, Vol 16, Iss 12, p 1559 (2024)
Publisher Information: MDPI AG, 2024.
Publication Year: 2024
Collection: LCC:Pharmacy and materia medica
Subject Terms: pharmacometrics, autoimmune diseases, personalized medicine, PBPK modeling, PK/PD modeling, disease progression modeling, Pharmacy and materia medica, RS1-441
More Details: Autoimmune diseases (AIDs) are a group of disorders in which the immune system attacks the body’s own tissues, leading to chronic inflammation and organ damage. These diseases are difficult to treat due to variability in drug PK among individuals, patient responses to treatment, and the side effects of long-term immunosuppressive therapies. In recent years, pharmacometrics has emerged as a critical tool in drug discovery and development (DDD) and precision medicine. The aim of this review is to explore the diverse roles that pharmacometrics has played in addressing the challenges associated with DDD and personalized therapies in the treatment of AIDs. Methods: This review synthesizes research from the past two decades on pharmacometric methodologies, including Physiologically Based Pharmacokinetic (PBPK) modeling, Pharmacokinetic/Pharmacodynamic (PK/PD) modeling, disease progression (DisP) modeling, population modeling, model-based meta-analysis (MBMA), and Quantitative Systems Pharmacology (QSP). The incorporation of artificial intelligence (AI) and machine learning (ML) into pharmacometrics is also discussed. Results: Pharmacometrics has demonstrated significant potential in optimizing dosing regimens, improving drug safety, and predicting patient-specific responses in AIDs. PBPK and PK/PD models have been instrumental in personalizing treatments, while DisP and QSP models provide insights into disease evolution and pathophysiological mechanisms in AIDs. AI/ML implementation has further enhanced the precision of these models. Conclusions: Pharmacometrics plays a crucial role in bridging pre-clinical findings and clinical applications, driving more personalized and effective treatments for AIDs. Its integration into DDD and translational science, in combination with AI and ML algorithms, holds promise for advancing therapeutic strategies and improving autoimmune patients’ outcomes.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1999-4923
Relation: https://www.mdpi.com/1999-4923/16/12/1559; https://doaj.org/toc/1999-4923
DOI: 10.3390/pharmaceutics16121559
Access URL: https://doaj.org/article/97ee800ee34c46878e8e266b87dc039d
Accession Number: edsdoj.97ee800ee34c46878e8e266b87dc039d
Database: Directory of Open Access Journals
Full text is not displayed to guests.
More Details
ISSN:19994923
DOI:10.3390/pharmaceutics16121559
Published in:Pharmaceutics
Language:English